Anti-platelet Therapy Clinical Trial
Official title:
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
NCT number | NCT03601013 |
Other study ID # | DAPT-TR |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | March 1, 2019 |
Verified date | May 2019 |
Source | Cardiovascular Academy Society, Turkey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Coronary Artery Disease (CAD) is leading cause of death worldwide. Most of them underwent coronary angiography and they have to use dual anti-platelet therapy. As mentioned novel guidelines for CAD, the estimated number of patients requiring dual anti-platelet therapy has increased over time, and DAPT time is controversial. Acting on the behalf of 2017 ESC focused update on dual anti-platelet therapy in coronary artery disease developed in collaboration with EACTS guideline, this study is amid to determine PRECISE-DAPT score which predicts out of hospital bleeding risk in patients receiving dual anti-platelet treatment and to detect the prevalence of patients with high bleeding risk, and to determine DAPT score which predicts benefit/risk ratio of continuing or discontinuing dual ant-iplatelet therapy after 12 months and to detect the prevalence of patients with high ischemic or hemorrhagic complication risk in centers included in this study.
Status | Completed |
Enrollment | 963 |
Est. completion date | March 1, 2019 |
Est. primary completion date | November 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients that have acute coronary syndrome or percutaneous coronary intervention electively and with available admission heamoglobin, white blood cell and creatine clearance data and on dual antiplatelet therapy Exclusion Criteria: - Being under eighteen years old |
Country | Name | City | State |
---|---|---|---|
Turkey | Balikesir University | Balikesir |
Lead Sponsor | Collaborator |
---|---|
Cardiovascular Academy Society, Turkey |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ischemia | ischemic events of patients on dual antiplatelet therapy | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03908593 -
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
|
Phase 4 | |
Terminated |
NCT01810276 -
Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury
|
N/A | |
Completed |
NCT01647568 -
Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
|
N/A |